Plain-English translation of NCT06535529 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether or dapagliflozin—two different oral medications—can help treat acute decompensated heart failure more effectively when combined with standard intravenous diuretics. Both groups will receive the same IV diuretics (water pills) that help remove excess fluid from the body, but one group will also take and the other will take dapagliflozin to see which approach works better.
When your heart suddenly can't pump well enough, fluid builds up in your body causing swelling and breathing problems—a condition called acute decompensated heart failure. Doctors currently use IV diuretics to remove this excess fluid, but researchers want to know if adding one of these oral medications to the standard treatment could help patients recover faster or more completely.
You likely qualify if…
You likely don't qualify if…
Once you're enrolled, you'll be randomly assigned to receive either or dapagliflozin as an oral pill taken once daily for 3 days, along with the standard IV diuretics given through your IV line. You'll also receive an initial IV diuretic dose right after enrollment, followed by additional doses over the next 2 days. The medical team will monitor your response using a scoring system that measures how much swelling and fluid buildup you have.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
Egypt